RU2017114109A - Кристаллические модификации элобиксибата - Google Patents
Кристаллические модификации элобиксибата Download PDFInfo
- Publication number
- RU2017114109A RU2017114109A RU2017114109A RU2017114109A RU2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A RU 2017114109 A RU2017114109 A RU 2017114109A
- Authority
- RU
- Russia
- Prior art keywords
- elobixibate
- crystalline
- dihydrate
- liver
- anhydrous
- Prior art date
Links
- XFLQIRAKKLNXRQ-UUWRZZSWSA-N elobixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C=3C=CC=CC=3)C=C2S(=O)(=O)CC(CCCC)(CCCC)CN1C1=CC=CC=C1 XFLQIRAKKLNXRQ-UUWRZZSWSA-N 0.000 title 1
- 229950000820 elobixibat Drugs 0.000 title 1
- 108010007192 elobixibat Proteins 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 150000004683 dihydrates Chemical class 0.000 claims 14
- 206010010774 Constipation Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 230000005855 radiation Effects 0.000 claims 6
- 206010008635 Cholestasis Diseases 0.000 claims 5
- 238000002441 X-ray diffraction Methods 0.000 claims 5
- 230000007870 cholestasis Effects 0.000 claims 4
- 231100000359 cholestasis Toxicity 0.000 claims 4
- 210000004185 liver Anatomy 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000004930 Fatty Liver Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 210000000941 bile Anatomy 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000007803 itching Effects 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 201000011374 Alagille syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims 1
- 201000009331 Choledocholithiasis Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 206010019799 Hepatitis viral Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 229940125922 IBAT inhibitor Drugs 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000017855 Progressive familial intrahepatic cholestasis type 1 Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 201000004525 Zellweger Syndrome Diseases 0.000 claims 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 claims 1
- 230000004129 fatty acid metabolism Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 201000002162 progressive familial intrahepatic cholestasis 1 Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 201000001862 viral hepatitis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14190290.8 | 2014-10-24 | ||
| EP14190290.8A EP3012252A1 (en) | 2014-10-24 | 2014-10-24 | Crystal modifications of elobixibat |
| PCT/EP2015/074573 WO2016062848A1 (en) | 2014-10-24 | 2015-10-23 | Crystal modifications of elobixibat |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022119479A Division RU2022119479A (ru) | 2014-10-24 | 2015-10-23 | Кристаллические модификации элобиксибата |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017114109A true RU2017114109A (ru) | 2018-11-26 |
| RU2017114109A3 RU2017114109A3 (https=) | 2019-04-30 |
Family
ID=51786891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017114109A RU2017114109A (ru) | 2014-10-24 | 2015-10-23 | Кристаллические модификации элобиксибата |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10183920B2 (https=) |
| EP (3) | EP3012252A1 (https=) |
| JP (1) | JP6700263B2 (https=) |
| KR (1) | KR102498539B1 (https=) |
| CN (2) | CN112375044A (https=) |
| AU (1) | AU2015334883B2 (https=) |
| CA (1) | CA2959760C (https=) |
| ES (1) | ES2874573T3 (https=) |
| RU (1) | RU2017114109A (https=) |
| WO (1) | WO2016062848A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| KR101844184B1 (ko) * | 2017-07-21 | 2018-04-02 | 씨제이헬스케어 주식회사 | 아미노알킬벤조티아제핀 유도체의 용도 |
| CN111032019B (zh) | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | 考来烯胺颗粒、口服考来烯胺制剂及其用途 |
| CA3091338A1 (en) | 2018-03-09 | 2019-09-12 | Elobix Ab | Process for the preparation of elobixibat |
| CN112449637B (zh) | 2018-06-05 | 2024-03-19 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| PL3810581T3 (pl) | 2018-06-20 | 2025-04-28 | Albireo Ab | Modyfikacje kryształu odewiksibatu |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| TWI835997B (zh) | 2019-02-06 | 2024-03-21 | 瑞典商艾爾比瑞歐公司 | 苯并噻氮呯化合物及其用作膽酸調節劑之用途 |
| CN118852054A (zh) | 2019-02-06 | 2024-10-29 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
| KR20220061110A (ko) | 2019-09-09 | 2022-05-12 | 이에이 파마 가부시키가이샤 | 1,5-벤조티아제핀 화합물을 제조하기 위한 방법 |
| EP4069247B1 (en) | 2019-12-04 | 2025-03-26 | Albireo AB | Benzothiadiazepine compounds and their use as bile acid modulators |
| ES2973355T3 (es) | 2019-12-04 | 2024-06-19 | Albireo Ab | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| JP7696898B2 (ja) | 2019-12-04 | 2025-06-23 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| IL293379B2 (en) | 2019-12-04 | 2026-04-01 | Albireo Ab | Benzothia(dia)azepine compounds and their use as bile acid modulators |
| EP4188541B1 (en) | 2020-08-03 | 2024-12-25 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| WO2022101379A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| CA3196488A1 (en) | 2020-11-12 | 2022-05-19 | Albireo Ab | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CN117980295A (zh) * | 2022-08-02 | 2024-05-03 | 上海皓元医药股份有限公司 | 一种依洛西巴特晶型ii及其制备方法 |
| CN120379676A (zh) | 2022-11-03 | 2025-07-25 | 阿尔比里奥公司 | 治疗阿拉杰里综合征(algs) |
| AU2024369988A1 (en) | 2023-11-03 | 2026-04-09 | Albireo Ab | Treating pfic2 with odevixibat |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3539380A (en) | 1968-01-08 | 1970-11-10 | Upjohn Co | Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms |
| GB1530201A (en) | 1976-04-14 | 1978-10-25 | Pfizer Ltd | Process for the preparation of aminoglycoside antibiotics and intermediates therefor |
| GB1566609A (en) | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
| EP0019115B1 (de) | 1979-04-30 | 1983-01-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pankreozymin-Cholezystokinin aktive Peptide, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel |
| US4900757A (en) | 1988-12-08 | 1990-02-13 | Merrell Dow Pharmaceuticals Inc. | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane |
| IL95574A (en) | 1989-09-09 | 1994-11-11 | Knoll Ag | Colestyramine preparation |
| DE3930168A1 (de) | 1989-09-09 | 1991-03-14 | Knoll Ag | Verbesserte verabreichungsform fuer colestyramin |
| US5250524A (en) | 1990-12-06 | 1993-10-05 | Hoechst Aktiengesellschaft | Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals |
| EP0549967B1 (de) | 1991-12-20 | 1996-03-13 | Hoechst Aktiengesellschaft | Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JPH05186357A (ja) | 1991-12-31 | 1993-07-27 | Shigeo Ochi | 飲食物消化分解産物吸収抑制手段 |
| GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
| IT1257793B (it) | 1992-05-18 | 1996-02-13 | Composizione farmaceutica a base di acidi biliari in microgranuli a rilascio controllato | |
| DK0573848T3 (da) | 1992-06-12 | 1998-08-10 | Hoechst Ag | Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler |
| US5350584A (en) | 1992-06-26 | 1994-09-27 | Merck & Co., Inc. | Spheronization process using charged resins |
| ZA941003B (en) | 1993-02-15 | 1995-08-14 | Wellcome Found | Hypolipidaemic compounds |
| IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
| DE69425453T2 (de) | 1993-04-23 | 2001-04-12 | Novartis Ag, Basel | Wirkstoffabgabevorrichtung mit gesteuerter Freigabe |
| EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
| TW289020B (https=) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
| TW289021B (https=) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
| TW289757B (https=) | 1993-05-08 | 1996-11-01 | Hoechst Ag | |
| ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| CN1084741C (zh) | 1994-09-13 | 2002-05-15 | 孟山都公司 | 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬 |
| GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| AU724620B2 (en) | 1996-01-16 | 2000-09-28 | Sokol, Ronald J Dr. | Use of antioxidant agents to treat cholestatic liver disease |
| HUP9903047A3 (en) | 1996-03-11 | 2002-12-28 | G D Searle & Co Chicago | Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| AU3940897A (en) | 1996-07-24 | 1998-02-10 | Zumtobel Staff Gmbh | Adapter for a retaining means used to secure a built-in lamp in a mounting hole,or retaining means or built-in lamp provided with such an adapter |
| DE19633268A1 (de) | 1996-08-19 | 1998-02-26 | Hoechst Ag | Polymere Gallensäure-Resorptionsinhibitoren mit gleichzeitiger Gallensäure-Adsorberwirkung |
| GB9704208D0 (en) | 1997-02-28 | 1997-04-16 | Glaxo Group Ltd | Chemical compounds |
| PL336415A1 (en) | 1997-03-11 | 2000-06-19 | Searle & Co | Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors |
| DK0864582T3 (da) | 1997-03-14 | 2003-09-29 | Aventis Pharma Gmbh | Hypolidemiske 1,4-benzothiazepin-1,1-dioxider |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| AUPO763197A0 (en) | 1997-06-30 | 1997-07-24 | Sigma Pharmaceuticals Pty Ltd | Health supplement |
| ATE234829T1 (de) | 1997-12-19 | 2003-04-15 | Searle & Co | Verfahren zu herstellung von enantiomerisch- anreicherte tetrahydrobenzothiepin oxyden |
| GB9800428D0 (en) | 1998-01-10 | 1998-03-04 | Glaxo Group Ltd | Chemical compounds |
| US6346527B1 (en) | 1998-04-24 | 2002-02-12 | Fujisawa Pharmaceutical Co., Ltd. | Guanidine derivatives |
| US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19825804C2 (de) | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP1103552A4 (en) | 1998-08-07 | 2003-01-15 | Takeda Chemical Industries Ltd | BENZOTHIEPINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| PT1140190E (pt) | 1998-12-23 | 2003-02-28 | Searle Llc | Combinacoes de inibidores do transporte ileal dos acidos biliares e agentes sequestrantes dos acidos biliares usadas para problemas cardiovasculares |
| WO2000038727A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle Llc | Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications |
| JP2002533412A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびコレステリルエステル転送タンパク質阻害剤の組み合わせ |
| KR20020002367A (ko) | 1998-12-23 | 2002-01-09 | 윌리암스 로저 에이 | 심혈관 징후를 위한 조합물 |
| JP2002533415A (ja) | 1998-12-23 | 2002-10-08 | ジー．ディー．サール エルエルシー | 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ |
| JP2002536440A (ja) | 1999-02-12 | 2002-10-29 | ジー．ディー．サール エルエルシー | 回腸胆汁酸輸送およびタウロコール酸塩取り込みの阻害剤としての活性を有する新規１，２−ベンゾチアゼピン |
| DE19916108C1 (de) | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6287609B1 (en) | 1999-06-09 | 2001-09-11 | Wisconsin Alumni Research Foundation | Unfermented gel fraction from psyllium seed husks |
| JP2003523336A (ja) | 2000-02-18 | 2003-08-05 | メルク エンド カムパニー インコーポレーテッド | 糖尿病及び脂質障害のためのアリールオキシ酢酸 |
| SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
| WO2001068096A2 (en) | 2000-03-10 | 2001-09-20 | Pharmacia Corporation | Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| US6586434B2 (en) | 2000-03-10 | 2003-07-01 | G.D. Searle, Llc | Method for the preparation of tetrahydrobenzothiepines |
| TWI241195B (en) | 2000-04-10 | 2005-10-11 | Shionogi & Co | Preventive agent for bile acidic diarrhea |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| RU2241462C2 (ru) | 2000-07-28 | 2004-12-10 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция |
| FR2812886B1 (fr) | 2000-08-08 | 2002-11-08 | Assist Publ Hopitaux De Paris | Depistage d'un nouveau syndrome hepatique et ses applications |
| SE0003766D0 (sv) | 2000-10-18 | 2000-10-18 | Astrazeneca Ab | Novel formulation |
| EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2002053548A1 (fr) | 2000-12-27 | 2002-07-11 | Banyu Pharmaceutical Co.,Ltd. | Derives de la benzothiazepine |
| US6506921B1 (en) | 2001-06-29 | 2003-01-14 | Virginia Tech Intellectual Properties, Inc. | Amine compounds and curable compositions derived therefrom |
| GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
| GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| AU2002329387B2 (en) | 2001-09-08 | 2007-06-07 | Albireo Ab | Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
| AU2002332638A1 (en) | 2001-09-12 | 2003-03-24 | G.D. Searle Llc | Method for the preparation of crystalline tetrahydrobenzothiepines |
| GB0314079D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| GB0201850D0 (en) | 2002-01-26 | 2002-03-13 | Astrazeneca Ab | Therapeutic treatment |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
| GB0216321D0 (en) | 2002-07-13 | 2002-08-21 | Astrazeneca Ab | Therapeutic treatment |
| US7312208B2 (en) | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
| CN100494185C (zh) | 2002-08-28 | 2009-06-03 | 旭化成制药株式会社 | 新型季铵化合物 |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| US20060210633A1 (en) | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
| GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
| KR20070026392A (ko) | 2004-02-27 | 2007-03-08 | 아사히 가세이 파마 가부시키가이샤 | 신규 벤조티아제핀 및 벤조티에핀 화합물 |
| US20050197376A1 (en) | 2004-03-02 | 2005-09-08 | Fujisawa Pharmaceutical Co. Ltd. | Concomitant drugs |
| EP1593671A1 (en) | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| JP4896480B2 (ja) | 2004-10-01 | 2012-03-14 | 第一三共ヘルスケア株式会社 | 陰イオン交換樹脂の粒子状組成物 |
| US20090131395A1 (en) | 2005-05-05 | 2009-05-21 | Microbia, Inc. | Biphenylazetidinone cholesterol absorption inhibitors |
| DE102005033100B3 (de) | 2005-07-15 | 2007-01-25 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
| EP1928499B1 (en) | 2005-09-20 | 2011-06-29 | Novartis AG | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| WO2007120592A1 (en) | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Cgrp antagonist salt |
| GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| DE102006053635B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DE502007006208D1 (de) | 2006-11-14 | 2011-02-17 | Sanofi Aventis Deutschland | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102006053637B4 (de) | 2006-11-14 | 2011-06-30 | Sanofi-Aventis Deutschland GmbH, 65929 | Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| DK2200588T3 (da) | 2007-09-25 | 2019-07-01 | Solubest Ltd | Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf |
| BRPI0918499A2 (pt) | 2008-09-02 | 2015-12-01 | Usv Ltd | polímeros reticulados |
| WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| ES2687027T3 (es) | 2010-11-04 | 2018-10-23 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermedades hepáticas |
| US20120114588A1 (en) | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| WO2012064268A1 (en) | 2010-11-08 | 2012-05-18 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
| DK2637646T3 (en) | 2010-11-08 | 2016-08-29 | Albireo Ab | PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder |
| AU2012328526B2 (en) | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| EP3154523B1 (en) | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
| CN106659726A (zh) | 2014-06-25 | 2017-05-10 | Ea制药株式会社 | 固体制剂及其着色防止或着色减少方法 |
| CA2952405A1 (en) | 2014-06-25 | 2015-12-30 | Ea Pharma Co., Ltd. | Solid formulation and method for stabilizing the same |
| US9684018B2 (en) | 2014-11-19 | 2017-06-20 | Texas Instruments Incorporated | Current sense circuit that operates over a wide range of currents |
| ES2874669T3 (es) | 2016-02-09 | 2021-11-05 | Albireo Ab | Formulación oral de colestiramina y uso de la misma |
| CN108601739B (zh) | 2016-02-09 | 2022-01-04 | 阿尔比里奥公司 | 考来烯胺丸剂及其制备方法 |
| WO2017138878A1 (en) | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
-
2014
- 2014-10-24 EP EP14190290.8A patent/EP3012252A1/en not_active Withdrawn
-
2015
- 2015-10-23 AU AU2015334883A patent/AU2015334883B2/en active Active
- 2015-10-23 WO PCT/EP2015/074573 patent/WO2016062848A1/en not_active Ceased
- 2015-10-23 US US15/519,808 patent/US10183920B2/en active Active
- 2015-10-23 CN CN202011101686.5A patent/CN112375044A/zh active Pending
- 2015-10-23 ES ES15784385T patent/ES2874573T3/es active Active
- 2015-10-23 EP EP21167339.7A patent/EP3904344A1/en not_active Withdrawn
- 2015-10-23 CN CN201580055918.9A patent/CN107001301A/zh active Pending
- 2015-10-23 EP EP15784385.5A patent/EP3209649B1/en active Active
- 2015-10-23 JP JP2017519487A patent/JP6700263B2/ja active Active
- 2015-10-23 CA CA2959760A patent/CA2959760C/en active Active
- 2015-10-23 RU RU2017114109A patent/RU2017114109A/ru unknown
- 2015-10-23 KR KR1020177012754A patent/KR102498539B1/ko active Active
-
2018
- 2018-12-27 US US16/234,364 patent/US10519120B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107001301A (zh) | 2017-08-01 |
| RU2017114109A3 (https=) | 2019-04-30 |
| KR20170072908A (ko) | 2017-06-27 |
| EP3904344A1 (en) | 2021-11-03 |
| EP3209649B1 (en) | 2021-04-21 |
| AU2015334883B2 (en) | 2019-10-24 |
| US20170240516A1 (en) | 2017-08-24 |
| US20190177286A1 (en) | 2019-06-13 |
| JP2017537061A (ja) | 2017-12-14 |
| CN112375044A (zh) | 2021-02-19 |
| KR102498539B1 (ko) | 2023-02-09 |
| US10519120B2 (en) | 2019-12-31 |
| EP3012252A1 (en) | 2016-04-27 |
| WO2016062848A1 (en) | 2016-04-28 |
| CA2959760A1 (en) | 2016-04-28 |
| CA2959760C (en) | 2023-10-10 |
| US10183920B2 (en) | 2019-01-22 |
| JP6700263B2 (ja) | 2020-05-27 |
| EP3209649A1 (en) | 2017-08-30 |
| ES2874573T3 (es) | 2021-11-05 |
| AU2015334883A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017114109A (ru) | Кристаллические модификации элобиксибата | |
| JP2017537061A5 (https=) | ||
| RU2015150039A (ru) | Кристаллическая модификация | |
| JP7372957B2 (ja) | アミノピリミジンｓｓａｏ阻害剤 | |
| TWI822738B (zh) | 用於製備1,5-苯并噻氮呯化合物之方法 | |
| CN107250149A (zh) | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 | |
| JP2025508746A5 (https=) | ||
| US9012604B2 (en) | Triazanonane derivatives or pharmaceutically acceptable salt thereof for enhanced fluorine-18 labeling | |
| JP2022523383A5 (https=) | ||
| US20240287108A1 (en) | nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES | |
| HK1243401B (en) | Crystal modifications of elobixibat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HE9A | Changing address for correspondence with an applicant |